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Objectives. A systematic review of parental surveys about HPV and/or child HPV vaccination to understand parental knowledge,
attitudes, and behaviour before and after FDA approval of the quadrivalent HPV vaccine and the bivalent HPV vaccine. Search
Strategy. Searches were conducted using electronic databases limited to published studies between 2001 and 2011. Findings.T h e
percentage of parents who heard about HPV rose over time (from 60% in 2005 to 93% in 2009), as did their appreciation for the
HPV infection and cervical cancer link (from 70% in 2003 to 91% in 2011). During the FDA approval, there was a stronger vaccine
awareness but it has waned. The same pattern is seen with parents whose children received the HPV vaccine (peak at 84% in 2010
and now 36% in 2011) or the intention to vaccinate (peak at 80% in 2008 and now 41% in 2011). Conclusions. Parents had safety
concerns and wanted more information their physician from to recommend and to conﬁdently HPV vaccinate their children.
1.Background
Human papillomavirus (HPV) is the most common sexually
transmitted infection in the world and is an established
causative agent for cervical, anal, and penile cancers, as
well as genital warts in both men and women [1, 2]. It is
estimated that 75% of Canadians will experience an HPV
infection at least once in their lifetime, with the highest rates
of infection occurring in individuals under the age of 25 [3].
In June 2006, the US Food and Drug Administration (FDA)
approved the quadrivalent vaccine for use in the prevention
of HPV strains 6, 11, 16, and 18, which are associated with
70% of cervical cancer and 90% of genital warts cases [4, 5].
In October 2009, the bivalent HPV vaccine was approved by
the FDA for the prevention of HPV strains 16 and 18 which
areassociated with70% of cervicalcancercases[4,6].Unlike
the quadrivalent vaccine, the bivalent HPV vaccine does not
protect against strains of HPV that cause genital warts [6].
Both vaccines are administered in three doses over a period
of six months.
As a result of the approval of the HPV vaccines,
recent health policy discussions have introduced the idea
of adjusting the age of initial PAP smears from 18 years
old (or with sexual debut) to 21 or 22 years old (or with
sexual debut) [7]. Additionally, a move away from PAP
smears toward HPV viral testing for women over 30 with a
concurrent decrease in the frequency of PAP smear testing
from annually to every 3 to 5 years has been proposed [7].
These health policy shifts are rooted in the success of the
HPV vaccines to guard against cervical cancer. This success
is, necessarily, dependent on successful vaccine uptake.
Currently,policyismodelledonan80%uptakebyyoung
women, which means when combined with vaccination,
reducing the frequency of testing and increasing the age of
initial PAP smear would be part of an eﬃcient plan to reduce
cervical cancer. However, actual uptake of the vaccines is
relatively low and not consistent in all areas that the vaccine
is oﬀered. For example, in the province of Quebec where
there is a passive consent strategy to school immunizations
(i.e., parental consent must be explicitly withdrawn in a note2 Obstetrics and Gynecology International
to the school), there is an 80% vaccine uptake for grade-8
girls [8, 9]. However, in the province of Ontario, where the
school-based immunization program has an active consent
strategy (i.e., parental consent is explicitly given in a note
to the school), the vaccine uptake rate for grade 8-girls is
50% [8, 9]. By comparison, the acceptance of the hepatitis
B vaccine was accepted without diﬃculty yet both aim at
preventing disease that is sexually acquired. The acceptance
of the hepatitis B vaccine for grade-7 students in Ontario
was 79.8% (range 65.2% to 95.2%) and in Quebec the
acceptance for grade-8 students was between 85 and 95%
[8, 9]. The hepatitis vaccine is oﬀered to both boys and girls
and is marketed to prevent liver disease and liver cancer,
which is relatively rare in the developed world compared to
cervical cancer. Suggested reasons for a low vaccine uptake
rate range from low knowledge levels regarding HPV and
the HPV vaccine, to cost, to a perceived low eﬃcacy of
the vaccine. Recent literature has examined these possible
factors as they relate to adolescent attitudes towards HPV
vaccination[7].However,giventhatthevaccinesaretargeted
towards males and females in the 9- to 26-age group, with
emphasis placed on ages 11 and 12 in order to promote
inoculation prior to sexual debut [10] ,ak e yf a c t o ri nt h e
implementation of HPV vaccines is the extent to which
parentsacceptHPVvaccinationfortheirchildren.Inorderto
fullyunderstandtheissuessurroundingHPVvaccineuptake,
parental attitudes towards the vaccine must be examined.
2.Objectives
The purpose of this systematic paper is to compare the
ﬁndings of previous studies that have examined parental
knowledge, attitudes, and behaviours towards the HPV
vaccine.Particularemphasiswillbeplacedonchangeswithin
parental knowledge, attitudes, and behaviour following the
availability of the HPV vaccines. Beyond identifying trends
in uptake, the paper will also focus on factors that aﬀect
parental intentions to vaccinate their children against HPV.
Based on previous studies regarding vaccination, these
factors may include parental knowledge regarding cervical
cancer and STIs (i.e., genital warts); perceived risk and sever-
ity of cervical cancer and genital warts; attitudes towards
vaccines in general; issues concerning increase in sexual
activity or promiscuity; availability of health insurance to
cover vaccine costs. Additionally, a preliminary analysis of
parental attitudes towards STI-prevention interventions ver-
sus anticancer interventions will be conducted to determine
the policy implications of the two vaccines; one of which is
part of an anticancer strategy as well as STI (genital warts)
prevention and one of which only targets cervical cancer
prevention.
3. Method
3.1. Search Strategy. Prior to conducting the literature
search, a librarian was consulted for assistance in building
a comprehensive search strategy. Relevant research studies
were located through an extensive search of the elec-
tronic databases PubMed, Ovid MEDLINE, Embase, and
Cumulative Index of Nursing and Allied Health Literature
(CINAHL).Searcheswerelimitedtoonlythosestudieswhich
were published between 2001 and 2011 in an eﬀort to
obtainthemostrecentarticlesregardingparentalknowledge,
attitudes,andbehaviourbeforeandafterFDAapprovalofthe
quadrivalent HPV vaccine and the bivalent HPV vaccine.
A preliminary hand search of the literature was com-
pleted in order to identify appropriate keywords and medical
subject heading (MESH) terms. The terms that were selected
to be used in this paper were “HPV”, “parent” and “vaccine,”
with“parent-childrelations,”“papillomavirusvaccine,”“par-
ent or child parent relation,” and “wart virus vaccine” often
being utilized as synonyms. Search terms were combined
using the operators “AND” and “OR” to ensure that all
relevant articles were located.
3.2. Study Selection. A total of 325 articles were identiﬁed:
304 from the initial search strategy and an additional
21 articles were gathered from the hand search of the
literature. Following the removal of duplicates (n = 71), 254
articles were screened for inclusion in the paper (Figure 1).
Inclusion criteria included (a) the study was about parents
and their attitudes towards HPV and/or HPV vaccination;
(b) the report had cross-sectional data about the parent’s
knowledge, attitudes, or beliefs about HPV that were not
previously inﬂuenced by the research team with an inter-
vention. Exclusion criteria included (a) sample population
was not comprised of parents; (b) knowledge, attitudes,
and/or behaviours of parents not discussed in results; (c)
methodology of study did not include survey; (d) article was
not based on original research (i.e., the study was a literature
review); (e) the full article was not available in English. The
results of the study selection process are shown in Figure 1.
3.3. Data Collection and Abstraction. The data abstraction
form was created and was pilot tested on ﬁve articles. Once
the remaining modiﬁcations were made to the abstraction
form, three coders extracted the data based on the coding
information provided on the form. The data was then
entered into SPSS for analysis, with information being
transformed into percentages where possible. Initially, ﬁve
outcomes that correspond to parental knowledge, attitudes,
or behaviours were recorded. These ﬁve outcomes were that
the parents had heard of HPV, heard of the HPV vaccine,
knowledge of association between HPV and cervical cancer,
an intention to vaccinate their child, and vaccinated their
child(ren) with one or more doses of the vaccine. Following
this initial analysis, an analysis of factors aﬀecting parental
attitudes toward the vaccines was conducted.
4. Results
4.1. Characteristics of Study Samples. The literature search
resulted in 53 studies that met inclusion criteria and were
included in this systematic paper [11–63]. All included stud-
ies have been listed by publication date, research question,
and focus in Figure 4. Publication dates were between the
years of 2004 and 2011 with the majority of the studies
being published in 2009 (28.3%) and 2010 (34.0%). SurveysObstetrics and Gynecology International 3
Original articles n = 254
n = 254 Sample population is not comprised of
parents = 53
n = 201
Knowledge, attitudes, or behaviours of
parents are not discussed = 17
n = 184
Methodology is not a survey = 124
n = 60 Article is not a research report = 4
n = 56
Total included = 53 Total excluded = 201
Article is not in english = 3
Figure 1: Inclusion and exclusion process.
were administered to parents in 2007 or earlier in 60.4% of
the studies. The majority of the studies were conducted in
North America (USA: 56.6%; Canada: 3.8%), however, the
European Union (24.5%), Asia (9.4%), and New Zealand or
Australia (5.7%) were also represented. Figure 2 highlights
the geographic representation of the sample. Forty-one
percent of studies were conducted in a school or medical
setting, while 45.3% used some form of population-based
sampling (e.g., census or government data, random digit
dialling, or an existing longitudinal study), and 13.2%
used other sampling procedures. These “other” sampling
procedures included pretest data from an educational HPV
intervention or mixed methods. Figure 3 demonstrates the
methodology of the studies in the sample.
The total number of parents included in this study was
54,194 with a median study sample size of 506, and a
mean study sample size of 1,022 (SD = 2,099). Six studies
only reported “parents” and did not diﬀerentiate between
mothers and fathers. Twenty-three studies (43%) reported
mothers’ responses only. Of those studies that reported both
mothers’ and fathers’ attitudes, the majority of respondents
were mothers with the average sample size of mothers at
82.3% (minimum: 47.7% and maximum: 95.1%).
4.2. Framework for Analyses. Studies posed a wide variety
of research questions; in order to simplify analyses, each
study’s central question and results were grouped according
to whether they were concerned with parental knowledge of
HPV, parental behaviours toward the HPV vaccines, parental
intent to vaccinate their children against HPV (attitudes), or
a combination of the three factors (Table 1).
Of the 53 studies included, 73.6% (39/53) attempted to
gauge parental knowledge of HPV and the HPV vaccine.
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Figure 2: Location of study.
(Number of studies and total number of parents)
(n = 53 studies)
10038 39844
4312
22 24 7
Convenience sample Census or random
sampling procedure
1
10
100
1000
10000
100000
Number of studies
Number of parents
Study methodology
Other
(e.g., school, clinic, etc.)
Figure 3: Study methodology.
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Figure 4: Heard of HPV.
This ranged from whether parents were aware of HPV to
whetherparentscouldcorrectlyidentifyHPVasthecausative
agent of cervical cancer. Thirty-eight percent (20/53) of
studies focused on parental behaviour (i.e., whether parents
had already inoculated their child or children against HPV
with either of the two vaccines available). Finally, 92.5%
(49/53) of studies focused on parental attitudes toward the
vaccine (whether parents intend to vaccinate their children
against HPV). Many studies also focused on factors aﬀecting
parental attitudes and behaviour regarding the HPV vaccine.
These factors included perceived vaccine eﬃcacy; vaccine
safety; perceived threat of HPV. They will be discussed more
thoroughly in the section regarding factors and barriers.4 Obstetrics and Gynecology International
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4.3. Knowledge Trends. Three primary knowledge questions
were examined: whether parents had heard of HPV, whether
they had heard of the HPV vaccine, and whether they could
correctly identify the relationship between HPV and cervical
cancer. Of the 53 studies, 19 studies (36%) asked parents
whether they had heard of HPV prior to being included in
the study (Figure 4).
Parental awareness of HPV increased in 2008 and 2009.
Of the 53 studies, 15 studies (28%) asked parents whether
they had heard of the HPV vaccines prior to being included
in the study (Figure 5).
Parental awareness of the HPV vaccine spiked in 2007
with a mean percentage of 59% compared to 14% in 2006.
Awareness continued to climb to 65% in 2008 and dropped
oﬀ slightly to 47% by 2010. These years are of particular
interest since they mark the introduction and availability of
the quadrivalent HPV vaccine and the bivalent HPV vaccine.
Of the 53 studies, 5 studies (9%) asked parents if they could
identify the relationship between cervical cancer and HPV
(Figure 6).
It is important to note that only 5 studies asked parents
to make the connection between HPV and cervical cancer. In
the study in which data were collected most recently (2011),
an average of 74% of parents could correctly identify the
relationship between HPV and cervical cancer. With only
5 studies examining parental knowledge of the relationship
between HPV and cervical cancer, it is diﬃcult to make any
connections between knowledge and the introduction and
availability of the HPV vaccine.
4.4. Behaviour Trends. Of the 53 studies, 17 studies (32%)
asked parents whether their child or children had already
been vaccinated against HPV (Figure 7).
Following the availability of the quadrivalent HPV
vaccine in 2007, studies began asking whether parents had
already vaccinated their children against HPV. The highest
percentages of parents who had vaccinated their children
against HPV occurred in 2009 and 2010. This is following
the introduction and availability of the bivalent HPV vaccine
in 2009.
4.5. Attitude Trends. Of the 53 studies included, 30 studies
(57%) asked parents whether they intend to vaccinate their
child or children against HPV (Figure 8).
The highest percentage of parents who intend to vacci-
nate their children (86%) occurs in studies where the data
were collected in 2005, prior to the release of the ﬁrst HPV
vaccine. Intent increases in 2008 to 80% of parents from67%
in2007andthengraduallydecreasesin2009,2010,and2011.
All three knowledge components have increased from
pre-2007 studies to post-2007 studies. While levels of uptake
pre-2007 and post-2007 cannot be compared, intent to vac-
cinate has decreased from pre-2007 to post-2007 (Table 2).
4.6.FactorsAﬀectingParentalDecisiontoVaccinate. Ofthe53
studies included, 81% made some mentioning of examining
barriers to parental intent to vaccinate. Parental experiences
and demographic characteristics were too mixed to show any
2005 2007
Year data collected
1
10
100
1000
10000
2008
Parents who have heard of HPV vaccine (n = 15 studies)
147
26
2
24
14
1
1879 1791
191
7
4
59 65
47
1
2006 2010
Number of parents
Average percentage
Number of studies
Figure 5: Heard of HPV vaccines.
1
10
100
1000
Parents who understood connection between HPV and cervical cancer
(n = 5 studies)
2003 2004
354 173 797 91
74 49 8 70
2
2007 2011
1 1 1
Number of parents
Average percentage
Number of studies
Year data collected
Figure 6: Cervical cancer and HPV.
Parents whose child had received HPV vaccine
(n = 17 studies)
668 825 1318
378
233
25 33 65 84
36
7 7
1 1 1
2007 2008 2010 2009 2011
Year data collected
1
10
100
1000
10000
Number of parents
Average percentage
Number of studies
Figure 7: Received HPV vaccine.
1
10
100
1000
10000
100000
2005 2007
Year data collected
2008 2006 2010 2009 2011 2003 2004
Number of parents
Average percentage
Number of studies
278
1169
1047 1677
23439
3156 1413
191 50
55 54 86 68 67 80 77 47 41
3 5
12
4 2 1 11 1
(n = 30 studies)
Parents who intend child to receive HPV vaccine
Figure 8: Intent to inoculate against HPV.Obstetrics and Gynecology International 9
Table 2: Summary of trends prior to 2007 and after 2007.
Number of studies Range values 2007 or earlier Number of studies Range values 2008 or later
2007 or earlier min % max % 2008 or later min % max %
Heard of HPV 12 59.0 59.5 7 64.7 93.0
Heard of HPV vaccine 10 14.0 58.7 5 47.0 64.5
Understood connection
between HPV and
Cervical Cancer
4 8.0 70.0 1 53.4 91.0
Parent intends to
vaccinate child
22 54.0 86.0 8 47.0 79.5
Child is vaccinated HPV NA NA 17 24.9 84.0
clear pattern within the 53 studies. Cost factors were also
mentioned, but were diﬃcult to compare across studies.
4.7. Knowledge
Parents Concerned about the Safety of the HPV Vaccine. In
20 studies (37%), parents expressed concerns about vaccine
safety and the potential side eﬀects of the HPV vaccine
[13, 15, 20, 23, 30, 32, 33, 35, 37, 39, 41, 42, 46–48, 52–
54, 60, 61].
Parents Wanted More Information about the Vaccine to Make
an Informed Decision as to Whether They Should Vaccinate
Their Child with the HPV Vaccine. In 13 studies (25%),
parents needed more information about HPV vaccination
[17, 30, 34, 41, 42, 46–48, 51, 52, 54, 60, 62].
4.8. Attitudes
Parents Who Were Concerned about the Potential Risk of
Cancer Were More Likely to Vaccinate for HPV. In 16 studies
(30%), parents mentioned a concern about cancer risk as
increasing the likelihood of HPV vaccination. Parents who
believed it was likely that their daughters might contract
HPV [13, 15, 18, 31–33, 50, 52], develop cervical or penile
cancer [13, 18, 20, 30, 31, 39, 47, 50, 53, 60, 62, 63] or genital
warts [13, 18, 47, 62] were more likely to vaccinate their
daughters.
Parents Agreed That Children Should Be Older and Sexually
Active to Receive the Vaccine. There were 10 studies (19%)
that mentioned the child’s age aﬀecting the parents’ decision
to vaccinate. Parents were less likely to vaccinate their
children if they believed their children were too young or not
sexually active [34, 40, 44, 48]. Some studies indicated that
parents were more likely to vaccinate their children if they
were sexually active [23] or older [32, 34, 53–55, 57].
Mixed Opinions About Parental Concerns for Increased or
More Risky Sexual Activity If Child Is Vaccinated. Parents
were not concerned that their children would become
sexually active if they were given the HPV vaccine in 13
studies (25%) [12, 14, 17, 28, 32–34, 39, 42, 46, 51, 60, 62],
while in six studies (13%), parents expressed concerns that
the HPV vaccine might encourage earlier sexual initiation,
or more risky sexual behaviours in their children [15, 23, 43,
48–50, 61].
4.9. Behaviours
Parents Looked to Their Physicians to Recommend the HPV
Vaccine. In 17 studies (32%), parents indicated that having
their doctors recommend the vaccine increased the likeli-
hood of HPV vaccination [17, 19, 24, 28, 30–35, 41, 47, 51–
53, 60, 62].
Parental Attitudes towards Vaccines Generally Indicated
Whether They Were in Favour of Vaccinating Their Children
for HPV. Parents who had previously vaccinated their
children against meningitis [19] or had a general belief in
the eﬃcacy of vaccines [15, 24, 25, 32, 45, 48–50, 62]w e r e
morelikelytovaccinate(10studiesor19%).Parentswhohad
refused previous vaccines for their children [11, 18, 45, 47,
63] and had concerns about too many vaccinations [45, 60]
were less likely to vaccinate (6 studies or 11%).
5. Discussion
This paper reviews the parental knowledge, attitudes, and
behaviours toward having their daughters and sons vacci-
nated against cervical cancer. The parents in these studies
were largely from a high resource background. The percent-
age of parents that participated in these surveys who had
heard about HPV clearly rose over time (from 60% in 2005
to 93% in 2009). Parents’ appreciation for the link between
HPV infection and cervical cancer did rise (70% in 2003
to 91% in 2011). During the era of FDA approval of the
vaccines, there appeared to be stronger awareness of the
vaccines and this has waned with time. This same pattern
is seen with the percentage of parents whose children had
received the HPV vaccine (high of 84% in 2010 and now
36% in 2011). Unfortunately, this pattern is also seen with
the intention to have a child vaccinated against HPV (peak at
80% in 2008 and now 41% in 2011).
In terms of barriers against the vaccine, parents still have
safety and side-eﬀect questions and they want more infor-
mation. Parents view the vaccine like the oral contraceptive
pill; it is best to invest in it only when you become at risk
(i.e., you are sexually active). Parents who have high cancer10 Obstetrics and Gynecology International
worries and receive strong messages about HPV risks are
more likely to advocate for the HPV vaccine. Parents look
to their physicians to recommend the vaccine.
The strengths of this study are that it involves infor-
mation gathered from a large number of parents from
several countries. It shows trends in knowledge, attitudes,
and behaviours over a time period just preceding the
FDA approval of the vaccine; during the approval phase
when there were extensive educational campaigns both by
the pharmaceutical companies, professional societies, and
media, after the FDA approval. The limitations of this study
was an inability to validate parental responses, for example,
determining how many parents had their child vaccinated
with at least one dose of the vaccine.
It will be interesting to see if there are changes in
parental attitudes as the types of information about HPV
and the HPV vaccine continue to ﬂood the literature. The
information about the role of oncogenic HPV in more than
cervical cancer is certainly evolving. We are just beginning
to grasp the prevention implications of the HPV vaccine in
the prevention of anal, oropharengeal, and a proportion of
vulvovaginal, and penile cancers. The recent approval of the
vaccine in young men may have an impact on decreasing
condyloma transmission and having an impact on the rise
of anal dysplasia/cancer in the male having sex with male
population. As the cervical screening strategy moves toward
primary HPV testing, this will also enhance education of the
population. Although cost did not emerge as a signiﬁcant
barrier, as the vaccine prices continue to fall, it will be
fascinating to see the impact on parental attitudes and
behaviour. As public health looks at successful population-
based prevention strategies, it will be interesting to look
at parental attitudes toward passive consent versus active
consent in school-based vaccination programs. Time will
provide information on how durable the vaccine is and long-
term sequelae; whether this will inﬂuence parental attitudes
remains to be seen.
In terms of future implications for policy, when the goal
is to preserve the health of the population, certainly the
passive consent approach, whether it is for vaccination or
cervical screening, seems to be showing profound beneﬁts.
There is preliminary data that shows women who are
vaccinated have less need for cervical precancer procedures
like biopsies and treatment, however, how this will impact
guidelines and availability of such services in the future
remains to be seen.
6. Conclusion
Initial awareness of the virus and the ability of the virus to
cause cancer have increased in the time period under study.
However, awareness of the vaccine, intent to vaccinate, rates
of vaccination rose during the initial introduction of the
HPV vaccine but have fallen in subsequent years. Surveys
have conﬁrmed that parents want more knowledge and
reassurance from their physicians that the HPV vaccine is
safe for their children to receive. Policy programs, aimed at
increasing HPV vaccination rates as part of an overall HPV
strategy to reduce the incidents of cancers and infections
caused by the virus, will need to heed the parents’ concerns
and information needs to be eﬀective.
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